Autistic children and adults fall asleep, stay asleep, and sleep through the night at meaningfully lower rates than the general population — research reviews put sleep problems at 40–83% of autistic children, with sleep-onset insomnia (trouble falling asleep) the single most common issue, at roughly 65%.1 Melatonin is the best-studied supplement for this specific symptom, with genuine double-blind, placebo-controlled trial evidence behind it — most of it in autistic children, including a large, prescription-strength trial that led to regulatory approval in Europe and Canada.4 None of that evidence means melatonin treats autism itself — autism isn't a disease, and no supplement changes it. It means melatonin has real support for helping with one common, exhausting, co-occurring symptom: sleep difficulty. It's also worth saying plainly up front: the strongest trial evidence is pediatric, and Proco's melatonin-containing products are formulated for adults, not children. If you're a parent or caregiver considering melatonin for an autistic child, that's a conversation for a pediatrician, not an adult supplement label.
How common are sleep difficulties in autistic people?
Very common — more common than almost any other co-occurring feature of autism. A research review on sleep in autistic children published by the National Institutes of Health puts the figure at 40–83% of children affected by some form of sleep disturbance, with several individual studies clustering closer to 70–80%.1 Sleep-onset insomnia (taking a long time to fall asleep) is the single most frequently reported issue, at roughly 65% on average across the studies reviewed, and sleep problems in autistic children are consistently found to be more common than in age-matched, non-autistic children.1
This isn't only a childhood pattern. Sleep Foundation, summarizing the adult research literature, reports that nearly 80% of autistic adults experience sleep disturbances — difficulty falling asleep, frequent night waking, and early morning waking with an inability to get back to sleep are the most commonly described issues.2 Autism itself is also more common than older estimates suggested: the CDC's most recent surveillance data puts prevalence at roughly 1 in 31 children (about 3.2%) — which, combined with sleep-difficulty rates this high, means a genuinely large number of people are dealing with chronic, disruptive sleep problems that standard sleep-hygiene advice often doesn't fully resolve.3
What the melatonin trials actually show
Melatonin is, by a wide margin, the most-studied supplement for sleep problems in autism. A 2011 systematic review and meta-analysis pooled the available research — including five double-blind, placebo-controlled randomized trials — and found melatonin use was associated with significant improvements in sleep duration, with large effect sizes, and minimal reported side effects across the trials reviewed.5
The strongest single piece of evidence since then is a large randomized, double-blind, placebo-controlled trial of a prolonged-release melatonin formulation, led by pediatric sleep researcher Paul Gringras and colleagues, in children and adolescents with autism spectrum disorder and confirmed insomnia. The trial found statistically significant improvements in sleep latency (time to fall asleep), total sleep time, and sleep continuity compared with placebo, alongside a favorable safety profile and minimal adverse effects that were maintained with longer-term use.4 That trial and its follow-up studies were substantial enough to support regulatory approval of a prescription prolonged-release melatonin product for insomnia in autistic children in the EU and, more recently, Canada — a level of evidence most supplement ingredients never reach.4
The evidence is real. It's also mostly pediatric, mostly prescription-strength, and specific to one symptom — not a reason to treat autism itself as something a supplement addresses.
It's worth being precise about what these trials measured and who was in them. They enrolled children and adolescents already diagnosed with autism spectrum disorder and a confirmed sleep-onset problem, they used a specific prolonged-release formulation and dosing protocol developed and tested for that population, and the outcome was improved sleep — not any change to autism's core features. That distinction matters both scientifically and ethically: autism is a form of neurological difference, not an illness to be corrected, and the trials were never designed to test whether melatonin does anything to autism itself. They tested whether it helps kids who are autistic and can't sleep, actually sleep.
Why this evidence base matters for adults too — with one important caveat
The general dose-response evidence for melatonin in adults follows a similar pattern to what the pediatric autism trials found: a 2024 systematic review and dose-response meta-analysis of randomized controlled trials found melatonin's effect on sleep onset increases progressively with dose, peaking around 4mg, and that taking it a few hours before the target bedtime outperforms the more common habit of taking it 30 minutes before bed.6 That's general population and general adult sleep-onset evidence, not an autism-specific adult trial — the trial base specifically in autistic adults is much thinner than in autistic children, and this is an honest gap in the research, not something we're going to paper over. What autistic adults with sleep-onset difficulty are left with today is the same solid general-population melatonin evidence everyone else has access to, plus a reasonable, evidence-consistent expectation — not yet a dedicated adult-autism RCT — that the same basic mechanism (shifting a delayed or irregular circadian signal) is likely to apply. We cover the full adult dose-response and safety picture, including where consumer products tend to fall short of the studied dose, in our melatonin dose-response deep dive.
Where Proco's products fit — and where they don't
Sleep Support (10mg melatonin per serving) and Sleep Formula (2mg melatonin per serving, individually dosed alongside valerian, chamomile, GABA, L-tryptophan, lemon balm, and passion flower) are formulated for adults. Neither product is intended for, dosed for, tested in, or marketed to children of any diagnosis or neurotype, autistic or not. The strongest melatonin-autism trial evidence — the Gringras trials and the regulatory approvals built on them — used a specific pediatric prolonged-release prescription formulation, in specific pediatric doses, under clinical supervision. That is a meaningfully different product, dosed and delivered differently, than an adult over-the-counter supplement, and the two should not be treated as interchangeable.
If you're a parent or caregiver of an autistic child struggling with sleep, the right next step is a conversation with a pediatrician or your child's care team — not substituting an adult supplement, ours or anyone else's. A pediatrician can weigh dose, formulation, timing, interactions with any other medications, and whether melatonin is appropriate at all for that specific child. For autistic adults evaluating melatonin for their own sleep-onset difficulty, the same general adult evidence, dosing, and precautions that apply to anyone else apply here too — see the dose-response article linked above before assuming more is better.
Bottom line
Sleep-onset and sleep-maintenance difficulty is one of the best-documented co-occurring features of autism, affecting a large majority of autistic children and a comparably high share of autistic adults. Melatonin is the supplement with the most rigorous trial support for that specific symptom — including a genuinely strong, prescription-grade pediatric evidence base that's rare in this category. What none of that evidence supports is treating melatonin, or any supplement, as something that addresses autism itself. It addresses sleep. For autistic adults, general adult melatonin evidence applies, with adult-appropriate products; for autistic children, the right move is a pediatrician's guidance, not an adult supplement aisle.
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition. This article does not describe a treatment for autism — autism is not a disease — and the products discussed are formulated for adults; they are not intended for, dosed for, or marketed to children.
References
- Sleep in Children with Autism Spectrum Disorder: A Review. PMC, National Institutes of Health. pmc.ncbi.nlm.nih.gov
- Autism and Sleep Issues. Sleep Foundation. sleepfoundation.org
- Prevalence and Early Identification of Autism Spectrum Disorder Among Children Aged 4 and 8 Years — Autism and Developmental Disabilities Monitoring Network, 16 Sites, United States, 2022. MMWR, CDC. cdc.gov
- Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL. Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 2017. pubmed.ncbi.nlm.nih.gov
- Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Developmental Medicine & Child Neurology, 2011. onlinelibrary.wiley.com
- Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug: Systematic Review of RCTs and Dose-Response Meta-Analysis. Journal of Pineal Research, 2024. onlinelibrary.wiley.com
Related reading: Melatonin: The Real Dose-Response Evidence and The Science of Deep Sleep: Separating What Works from What's Marketing.
Want to know what's actually in what you take? Join the list — no spam, just it straight.